Herceptin Followed by Chemotherapy in Treating Women With Metastatic Breast Cancer That Overexpresses HER2
Randomized Phase III Trial of Herceptin® Followed by Chemotherapy Plus Herceptin® Versus the Combination of Herceptin® and Chemotherapy as Palliative Treatment in Patients With HER2- Overexpressing Advanced/Metastatic Breast Cancer.
Sponsor: Swiss Cancer Institute
Terminated
Trial is Life long follow-up: to reduce ressources and costs - trial terminated prematurely.
Other terminated trials from Swiss Cancer Institute
This PHASE3 trial investigates Breast Cancer and is currently terminated or withdrawn. Swiss Cancer Institute leads this study, which shows 15 recorded versions since 1999 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
15 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Aug 2025 — Sep 2025 [monthly]
Terminated PHASE3
-
Sep 2024 — Aug 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
May 2023 — Jul 2024 [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
▶ Show 10 earlier versions
-
Apr 2022 — May 2023 [monthly]
Active Not Recruiting PHASE3
-
Oct 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE3
-
Mar 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE3
-
Feb 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
-
Apr 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE3
-
Aug 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE3
-
Dec 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Aug 1999
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Swiss Cancer Institute
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aarau, Switzerland , Baden, Switzerland , Basel, Switzerland , Bellinzona, Switzerland , Bern, Switzerland , Chur, Switzerland , Geneva, Switzerland , Lausanne, Switzerland , Lugano, Switzerland , Milan, Italy and 5 more locations